At a glance

ClinicalIndex Comparison Record

N/ACompleted· 40 enrolled / 40 target

Drug / intervention

Not specified

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07655739

NCT07655739N/ACompletedHigh Momentum (4.0/mo)Completion was 5mo ago

Compare CT.gov

Temporal Changes in Fractalkine (CX3CL1) Levels Following Sleeve Gastrectomy and Their Association With Weight Loss: A Prospective Study

Mehmet Buğra Bozan·observational·Posted Jun 18, 2026·Updated Jun 18, 2026

In Brief

An observational study for Obesity & Overweight. Completed, enrolled 40 participants across 1 site.

Signals

Enrolling ahead of pace

Detailed Summary

Fractalkine (CX3CL1) is a unique chemokine involved in leukocyte adhesion, migration, and obesity-associated adipose tissue inflammation. Although bariatric surgery results in substantial weight loss and metabolic improvement, the temporal pattern of circulating CX3CL1 levels following laparoscopic sleeve gastrectomy (LSG) remains poorly understood. This study aimed to evaluate longitudinal changes in serum CX3CL1 levels after LSG and to investigate their association with postoperative weight loss.

Study Details

Study Typeobservational

Allocation--

Masking--

Primary Purpose--

ConditionsObesity & Overweight

CountriesTurkey (Türkiye)

Collaborators--

Timeline

N/ACompletedFinished

2026

Enrollment StartSep 2025

Primary CompletionJan 2026

Study CompletionFeb 2026

First PostedJun 2026

TodayJul 2026

First PostedJun 18, 2026

Enrollment StartSep 4, 2025

Primary CompletionJan 4, 2026

Study CompletionFeb 4, 2026

TodayJul 2, 2026

Enrollment to primary: 4 monthsPosted 14 days ago

Arms & Interventions

Obesity Surgery Patients undergoing Laparoscopic Sleeve Gastrectomyother

Obesity Surgery Patients undergoing Laparoscopic Sleeve Gastrectomy